Corporate Thrones: Indian pharma over last 20 years
As CNBC-TV18 turns 20, track the evolution of Indian pharmaceutical industry over the past two decades with industry stalwarts Kiran Mazumdar Shaw of Biocon, Umang Vohra of Cipla and A Vaidheesh of GSK Pharma.
As CNBC-TV18 turns 20, track the evolution of Indian pharmaceutical industry over the past two decades with industry stalwarts Kiran Mazumdar Shaw of Biocon, Umang Vohra of Cipla and A Vaidheesh of GSK Pharma.
The pharmaceutical industry has grown to become one of India’s largest economic sectors in terms of both employment and revenue generation in the past 20 years. Also a sector, that comprises 5 percent of total Indian exports today.
Pharma is a sector that is expected to grow at a 22 percent compounded annual growth rate to $350 billion by 2022. Indian pharma companies today are the largest supplier of drugs globally with a 20 percent market share. One of the biggest generics supplier to the US Market.
Four out of every ten generic drugs sold in the US, the largest pharma market, is manufactured by an Indian company. India also boasts of the largest number of USFDA compliant plants outside the US.
To discuss how the industry has evolved over the last 20 years and what is the way forward, CNBC-TV18 in it's special show Corporate Thrones speak with three industry titans Kiran Mazumdar Shaw, chairman and managing director of Biocon; Umang Vohra, managing director and global chief executive officer, Cipla and A Vaidheesh, managing director India, GSK Pharma.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
PM Narendra Modi takes oath for record third term
Jun 9, 2024 7:26 PM
Lok Sabha to get LoP after 10 years, opposition hopes deputy speaker gets elected
Jun 9, 2024 7:04 PM